GAST Laboratories launches Equine medical device

GAST Laboratories, a division of Absorbatox Pharmaceuticals, has officially launched Equine Balance™, a non-systemic medical device based on an inert modified molecular mineral aimed at treating gastro intestinal related disorders and lactic acid build-up in horses.

This is the world’s first veterinary and medical device, which is swallowed and then excreted again, bringing relief to horses without drug complications. Simply added to the horse’s feed, the technology is fully South African and the result of 22 years of intensive research by engineers, pharmacologists and veterinary physicians.

The launch of Equine Balance™ follows the introduction of Bowel Balance (a specific treatment regime for Irritable Bowel Syndrome or Spastic Colon in humans) in 2016. The same technology is also used in reducing non-steroidal anti-inflammatory induced gastric ulcerations and symptoms related to hangover due to intestinal insult.

Absorbatox Pharmaceutical’s Dr Jacques Snyman says Equine Balance™ treats symptoms associated with colic and hind-gut acidosis, gastro intestinal disturbances, discomfort, cramps, diarrhoea and acts as a mycotoxin and ammonia binder in horses. “It also reduces lactic acid build-up which is responsible for the delayed recovery time in horses especially after strenuous exercise.”

Equine Balance™ is also a free-radical scavenger and anti-oxidant. It binds heavy metals (cadmium, lead and mercury) and replaces them with calcium or magnesium. Its “sorptive” activity also allows it to bind biological amines such as histamine in the gut.

This reduces the allergic sequalae that horses have to a variety of environmental factors such as food and results in a reduction of laminitis, lethargy, irritability, grouchiness or difficulty in bending or collecting.

“It also reduces and assists in the prevention of gastric lesions in the foregut and hindgut of horses suffering from stomach ulcers and can be taken with or without anti-inflammatories,” says Dr Snyman.

In clinical research, Equine Balance™ has demonstrated effective binding of the following mycotoxins:

  • Deoxynivalenol
  • Ochratoxin A
  • Zearalenone

The device’s action results in an improved food conversion ratio, thereby improving the horse’s condition and performance.

Dr Snyman stresses that Equine Balance™ has no intrinsic pharmacological action. It is a medical device added to the feed with significantly enhanced ab- and adsorptive action potential.

Equine Balance™ should form part of a healthy horse’s monthly supplement regime and should be administered on the presentation of the symptoms mentioned above.

Absorbatox® Pharmaceuticals enjoys both ISO 9001:2015 and FDA accreditation and has been at the forefront of this medical device technology which is swallowed and subsequently excreted naturally.